¶ Cannabinoids
Disclaimer: This article is provided for educational and informational purposes only. It does not constitute medical advice. Consult a qualified healthcare professional before using cannabis or cannabinoid products for any health-related purpose.
¶ Overview
Cannabinoids are a class of diverse chemical compounds that interact with the endocannabinoid system (ECS) -- a complex cell-signaling network found throughout the human body and in other mammals. Cannabis (Cannabis sativa L.) produces over 100 identified cannabinoids, each with distinct chemical structures, pharmacological properties, and potential effects.
These compounds are classified as phytocannabinoids (plant-derived), distinguishing them from endocannabinoids (produced internally by the body) and synthetic cannabinoids (manufactured in laboratories). Understanding the chemistry and pharmacology of cannabinoids is essential for evaluating both the effects of cannabis and the growing market of cannabinoid-based products.
Figure 1: Molecular structures of major cannabis cannabinoids.
¶ The Endocannabinoid System (ECS)
¶ Discovery and Historical Context
The endocannabinoid system was discovered through a series of landmark experiments spanning three decades. The story begins with Raphael Mechoulam at the Hebrew University of Jerusalem, who in 1964 first isolated and synthesized Delta-9-THC, identifying it as the primary psychoactive constituent in cannabis. This breakthrough enabled researchers to ask a fundamental question: why does the human body have receptors that specifically respond to a plant compound?
The answer came in 1988 when Allyn Howlett and William Devane at St. Louis University identified the first cannabinoid receptor (later named CB1) in rat brain tissue. This was the first demonstration that the brain contained receptors specifically designed to bind cannabis-derived compounds. In 1992, Mechoulam's team, working with Devane and Hanus, isolated the first endogenous ligand for this receptor -- a molecule they named anandamide (from the Sanskrit ananda, meaning "bliss"). A second endocannabinoid, 2-AG (2-arachidonoylglycerol), was identified in 1995 by Mechoulam's group and independently by Raphael Mechoulam and Shimon Ben-Shabat.
The second cannabinoid receptor, CB2, was cloned and characterized in 1993 by researchers at the National Institute of Mental Health. The realization that the body produces its own cannabis-like compounds and has dedicated receptors for them -- an entire physiological system that had gone unrecognized until the 1990s -- was one of the most significant discoveries in modern neuroscience.
Note: The ECS was named after the plant that led to its discovery, not the other way around. Endocannabinoids and their receptors existed long before humans consumed cannabis. The system is evolutionarily ancient, found in mammals, birds, fish, and even some invertebrates. Some researchers have proposed that the ECS may represent a fundamental regulatory system for maintaining physiological homeostasis across many species.
¶ How Endocannabinoids Are Synthesized: The On-Demand Model
Unlike classical neurotransmitters (dopamine, serotonin, glutamate), which are synthesized in advance, packaged into synaptic vesicles, and stored until release, endocannabinoids are synthesized on demand from lipid precursors already present in cell membranes. This fundamental difference has profound implications for how the ECS functions.
The synthesis pathway works as follows:
- Precursor availability: Cell membranes contain phospholipids with arachidonic acid tails. When a postsynaptic neuron is depolarized (activated), calcium influx triggers enzymatic pathways.
- Enzymatic conversion: For anandamide (AEA), the enzyme N-acyl phosphatidylethanolamine-specific phospholipase D (NAPE-PLD) converts membrane phospholipids into AEA. For 2-AG, the enzymes phospholipase C (PLC) and diacylglycerol lipase (DAGL) work sequentially to produce 2-AG from membrane phosphatidylinositol.
- Immediate release: Once synthesized, endocannabinoids diffuse directly through the cell membrane -- they are not stored in vesicles.
- Rapid degradation: After fulfilling their signaling role, endocannabinoids are quickly broken down by enzymes. FAAH (fatty acid amide hydrolase) degrades anandamide, while MAGL (monoacylglycerol lipase) degrades 2-AG.
This on-demand synthesis means endocannabinoid signaling is local, transient, and activity-dependent. The body does not maintain a circulating pool of endocannabinoids the way it maintains pools of hormones or classical neurotransmitters. Instead, they are produced exactly where and when needed, act briefly, and are then destroyed.
¶ Retrograde Signaling: How Endocannabinoids Travel Backwards
The most distinctive feature of endocannabinoid signaling is its retrograde (backward) direction. In a typical synapse:
Presynaptic Neuron ──(neurotransmitter)──> Postsynaptic Neuron
^ |
| |
<──(endocannabinoid retrograde signal)──────┘
Step-by-step retrograde signaling:
- The postsynaptic neuron is activated by incoming neurotransmitters (glutamate, GABA).
- Calcium influx in the postsynaptic cell triggers on-demand synthesis of endocannabinoids from membrane lipids.
- Endocannabinoids diffuse backwards across the synaptic cleft (they are lipophilic and pass through membranes easily).
- They bind to CB1 receptors on the presynaptic terminal.
- CB1 activation inhibits voltage-gated calcium channels in the presynaptic neuron, reducing further neurotransmitter release.
- This creates a negative feedback loop: when the postsynaptic cell is overstimulated, it signals the presynaptic cell to "turn down the volume."
This retrograde mechanism is why the ECS is often described as the body's "dimmer switch" for neural signaling. It does not initiate signals; it modulates their intensity. This has direct implications for understanding cannabis effects: when THC enters the system, it hijacks this modulatory mechanism, broadly altering how the brain regulates neurotransmitter release across many circuits simultaneously.
¶ Orthosteric vs. Allosteric Binding
Understanding how cannabinoids interact with receptors requires distinguishing between two types of binding sites:
Orthosteric binding occurs at the receptor's primary (active) site -- the same site where the body's natural ligand binds. When THC binds to the orthosteric site of CB1, it mimics anandamide and directly activates the receptor. This is a "key in the lock" mechanism.
Allosteric binding occurs at a secondary site on the receptor, separate from the orthosteric site. When a molecule binds allosterically, it changes the receptor's shape, which in turn affects how the orthosteric site responds to its natural ligand. There are two types:
- Positive allosteric modulators (PAMs): Make the receptor more responsive to its natural ligand (amplify the signal).
- Negative allosteric modulators (NAMs): Make the receptor less responsive to its natural ligand (dampen the signal).
CBD acts as a negative allosteric modulator at CB1. It does not compete with THC for the orthosteric site; instead, it binds elsewhere on the CB1 receptor and changes its shape so that THC (and anandamide) bind less effectively. This is one of the primary mechanisms by which CBD can "take the edge off" THC's psychoactive effects -- it makes CB1 receptors less responsive to THC without blocking them entirely.
¶ ECS Core Components
| Component | Description | Location | Primary Function |
|---|---|---|---|
| CB1 Receptors | G protein-coupled receptors (Gi/o) | Primarily central nervous system (brain, spinal cord); also peripheral organs | Mediate psychoactive effects, pain modulation, appetite, memory |
| CB2 Receptors | G protein-coupled receptors (Gi/o) | Primarily immune cells, peripheral tissues, microglia | Immune modulation, inflammation regulation, pain |
| Anandamide (AEA) | Endogenous cannabinoid (endocannabinoid) | Throughout the body | "Bliss molecule" -- mood, appetite, pain, memory regulation |
| 2-AG (2-Arachidonoylglycerol) | Endogenous cannabinoid | Throughout the body | Most abundant endocannabinoid; pain, inflammation, immune function |
| FAAH | Fatty acid amide hydrolase (enzyme) | Throughout the body | Breaks down anandamide |
| MAGL | Monoacylglycerol lipase (enzyme) | Throughout the body | Breaks down 2-AG |
| GPR55 | Orphan G protein-coupled receptor | Brain, bone, endothelial cells | Emerging target; may be a third cannabinoid receptor |
| TRPV1 | Transient receptor potential vanilloid 1 | Sensory neurons, peripheral tissues | Pain perception, inflammation, body temperature |
| PPAR-gamma | Nuclear receptor (peroxisome proliferator-activated) | Cell nuclei | Gene regulation, metabolism, inflammation |
¶ How Phytocannabinoids Interact
Phytocannabinoids interact with the ECS through several mechanisms:
- Agonism: Binding to and activating a receptor (e.g., THC activates CB1 receptors)
- Antagonism: Binding to a receptor and blocking it from activation (e.g., THCV at low doses blocks CB1)
- Allosteric modulation: Binding to a secondary site on a receptor, altering how other molecules bind (e.g., CBD acts as a negative allosteric modulator at CB1)
- Enzyme inhibition: Preventing the breakdown of endocannabinoids (e.g., CBD inhibits FAAH)
- Reuptake inhibition: Blocking the reabsorption of endocannabinoids, increasing their availability
THC has a molecular structure similar enough to anandamide that it can bind directly to CB1 receptors, which is why it produces psychoactive effects. CBD, by contrast, does not bind strongly to CB1 or CB2 but influences the ECS through indirect mechanisms and interacts with other receptor systems (serotonin, vanilloid, and GPR55 receptors, among others).
¶ Why the ECS Matters for Understanding Cannabis Effects
The ECS's role as a universal modulatory system explains why cannabis produces such wide-ranging effects across different body systems. Because endocannabinoids regulate neurotransmitter release at synapses throughout the brain and body, introducing external cannabinoids (phytocannabinoids) affects:
- Pain circuits: Endocannabinoids normally dampen pain signals; THC amplifies this effect.
- Reward circuits: THC increases dopamine release in the nucleus accumbens by inhibiting GABA interneurons that normally suppress dopamine neurons.
- Memory circuits: CB1 receptors in the hippocampus modulate synaptic plasticity; THC disrupts short-term memory formation.
- Appetite circuits: Endocannabinoids in the hypothalamus regulate feeding behavior; THC stimulates appetite.
- Immune function: CB2 receptors on immune cells regulate inflammatory responses; cannabinoids modulate inflammation.
The fact that the ECS operates through retrograde, on-demand signaling also explains why cannabis tolerance develops: chronic exposure to external cannabinoids causes the brain to downregulate CB1 receptors (reduce their number on the cell surface) as a compensatory response to persistent overstimulation. This is the molecular basis for cannabis tolerance and the reason tolerance reverses after a period of abstinence.
Figure 2: The endocannabinoid system -- receptors, endocannabinoids, and metabolic enzymes.
¶ Chemical Structure of Cannabinoids
All phytocannabinoids in cannabis share a common biosynthetic origin but differ in their molecular architecture in ways that profoundly affect their pharmacological properties. Understanding these structural differences is essential for understanding why cannabinoids produce different effects despite their shared origin.
¶ Common Structural Framework
Most cannabinoids share a core dibenzopyran (benzopyran) ring system -- a fused tricyclic structure consisting of a benzene ring fused to a pyran ring, which is itself fused to a cyclohexene ring. Variations on this core structure -- including the position of double bonds, the presence or absence of functional groups, and the length of side chains -- determine each cannabinoid's unique properties.
¶ Structural Comparison of Major Cannabinoids
¶ Delta-9-THC (Delta-9-Tetrahydrocannabinol)
- Molecular formula: C21H30O2
- Molecular weight: 314.47 g/mol
- IUPAC name: (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol
Structure: The defining feature is the double bond at the 9th carbon position on the cyclohexene ring, a pentyl (5-carbon) side chain at position 3, and a closed pyran ring (the oxygen bridge connecting the benzene ring to the cyclohexene ring). The molecule has two chiral centers at positions 6a and 10a, giving it specific three-dimensional geometry.
Simplified structural diagram:
CH3
|
HO---C6----C10a---O
| | \
C7---C8----C9 C3---(CH2)4-CH3 (pentyl chain)
\\ | || |
C---C5---C4 CH3
|
CH3
Key: Double bond at C9=C10 (Δ9)
Pentyl side chain at C3
Hydroxyl (OH) at C1
Closed pyran ring
Binding implications: The closed pyran ring and the position of the double bond create a molecular shape that fits well into the CB1 receptor's binding pocket. The pentyl side chain is critical -- it anchors the molecule in the receptor's hydrophobic binding pocket. The hydroxyl group at C1 forms hydrogen bonds with amino acid residues in the receptor. This combination gives Delta-9-THC its high affinity for CB1 (Ki = 10-40 nM), making it the most psychoactive naturally occurring cannabinoid.
¶ Delta-8-THC (Delta-8-Tetrahydrocannabinol)
- Molecular formula: C21H30O2 (structural isomer of Delta-9-THC)
- Molecular weight: 314.47 g/mol
Structural difference from Delta-9-THC: The double bond is shifted from position 9 to position 8 on the cyclohexene ring. Everything else is identical.
Delta-9-THC: ...C8--C9=C10--C10a...
Delta-8-THC: ...C8=C9--C10--C10a...
(double bond shifts one position)
Binding implications: This seemingly small shift changes the molecule's three-dimensional conformation slightly, reducing its affinity for the CB1 receptor by approximately 20-30%. The result is that Delta-8-THC produces similar effects to Delta-9-THC but at roughly 50-75% potency. Users consistently report less anxiety and paranoia with Delta-8, which may relate to the altered binding kinetics at CB1.
¶ THCA (Tetrahydrocannabinolic Acid)
- Molecular formula: C22H30O4
- Molecular weight: 358.48 g/mol
Structural difference from THC: THCA has a carboxyl group (-COOH) attached to the benzene ring at position 2, adding 44 mass units (CO2) compared to THC. This carboxyl group makes the molecule larger, more polar, and unable to cross the blood-brain barrier effectively.
THCA structure vs THC:
THCA: HOOC---(benzene ring)---OH (carboxyl group present)
THC: H------(benzene ring)---OH (carboxyl group removed by heat)
Binding implications: The carboxyl group dramatically changes the molecule's shape and polarity. THCA does not fit into the CB1 receptor's binding pocket and therefore has negligible psychoactivity. However, THCA does interact with other targets including COX-1/COX-2 enzymes (similar to NSAIDs like ibuprofen) and TRPV1 channels, which may account for its anti-inflammatory and anti-nausea properties.
¶ THCV (Tetrahydrocannabivarin)
- Molecular formula: C19H26O2
- Molecular weight: 286.41 g/mol
Structural difference from THC: THCV has a propyl (3-carbon) side chain instead of the pentyl (5-carbon) side chain. This removes two carbons (C4H8) from the molecule.
Delta-9-THC: C3---CH2-CH2-CH2-CH2-CH3 (pentyl, 5 carbons)
THCV: C3---CH2-CH2-CH3 (propyl, 3 carbons)
Binding implications: The shorter side chain dramatically changes how THCV interacts with CB1. At low doses, THCV acts as a CB1 antagonist (it binds but blocks the receptor, preventing activation). At higher doses, it becomes a CB1 agonist (activating the receptor). This dose-dependent switch is unique among cannabinoids and explains why THCV can suppress appetite at low doses (blocking CB1) while producing mild psychoactive effects at high doses (activating CB1). The propyl chain also gives THCV a lower molecular weight, potentially affecting its membrane permeability.
¶ CBD (Cannabidiol)
- Molecular formula: C21H30O2
- Molecular weight: 314.47 g/mol
- IUPAC name: 2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
Structural difference from THC: CBD has an open (uncyclized) ring structure. In THC, the oxygen atom forms a bridge (pyran ring) between the benzene ring and the cyclohexene ring. In CBD, this bridge is broken -- the oxygen exists as a hydroxyl group (-OH) rather than as part of a ring. This is the single most important structural difference between THC and CBD.
THC (closed ring): CBD (open ring):
Benzene---O---Cyclohexene Benzene-OH + Cyclohexene
(pyran ring closed) (ring opened; no bridge)
Binding implications: The open ring structure gives CBD a completely different three-dimensional shape that does not fit into the CB1 receptor's binding pocket. Instead, CBD exerts its effects through indirect mechanisms: as a negative allosteric modulator at CB1 (changing the receptor's shape from a secondary site), as an agonist at 5-HT1A serotonin receptors, as an agonist at TRPV1 vanilloid receptors, and as an antagonist at GPR55. The structural openness also means CBD has very different pharmacological behavior from THC despite sharing the same molecular formula (they are structural isomers).
¶ CBDA (Cannabidiolic Acid)
- Molecular formula: C22H30O4
- Molecular weight: 358.48 g/mol
Structural difference from CBD: Like THCA relative to THC, CBDA has a carboxyl group (-COOH) on the benzene ring. It also retains CBD's open ring structure.
Binding implications: CBDA is non-psychoactive and has notably high affinity for the 5-HT1A serotonin receptor -- some studies suggest it may be even more potent than CBD at this target. This makes CBDA particularly interesting for anti-nausea and anti-anxiety applications. The carboxyl group prevents significant blood-brain barrier penetration, but CBDA may act on peripheral 5-HT1A receptors in the gut (the "enteric nervous system") to reduce nausea.
¶ CBG (Cannabigerol)
- Molecular formula: C21H32O2
- Molecular weight: 316.48 g/mol
Structural features: CBG has an open ring structure (like CBD) but with a different arrangement. It lacks the cyclohexene ring entirely -- instead, it has a simpler structure with a pentyl side chain and two hydroxyl groups. CBG is the non-cyclized precursor from which THCA, CBDA, and CBCA are synthesized in the plant.
Binding implications: CBG shows weak agonist activity at both CB1 and CB2 receptors but with much lower affinity than THC. It also acts as an alpha-2 adrenergic receptor agonist and 5-HT1A antagonist, contributing to its diverse pharmacological profile. The open-ring structure and the absence of a closed pyran system mean CBG interacts with receptors differently from THC.
¶ CBN (Cannabinol)
- Molecular formula: C21H26O2
- Molecular weight: 310.44 g/mol
Structural difference from THC: CBN is an oxidized degradation product of THC. During oxidation, the cyclohexene ring's double bond is lost, and the ring becomes aromatized (converted into an additional benzene ring). CBN has three aromatic rings instead of THC's two rings (one aromatic benzene + one partially saturated pyran).
THC oxidation to CBN:
THC: Benzene + Pyran (partially saturated) + Cyclohexene
│
│ (oxidation: loss of H2, aromatization)
▼
CBN: Benzene + Pyran (aromatized) + Benzene
(fully aromatic tricyclic system)
Binding implications: The aromatization changes CB1 affinity significantly. CBN binds to CB1 with approximately 10% the affinity of THC, explaining its much milder psychoactivity. The more planar (flat) aromatic structure may also affect how it interacts with other targets. CBN shows some activity at TRPA1 and TRPV2 channels, which may contribute to its purported sedative effects.
¶ CBC (Cannabichromene)
- Molecular formula: C21H30O2
- Molecular weight: 314.47 g/mol
Structural features: CBC has a closed pyran ring (like THC) but the arrangement of the ring system is different -- the benzene ring is connected to the cyclohexene ring in a different orientation, and the hydroxyl group is in a different position. CBC is a structural isomer of both THC and CBD.
Binding implications: CBC has very low affinity for CB1 and is therefore non-psychoactive. However, it shows significant agonist activity at TRPV1 and TRPA1 (transient receptor potential channels involved in pain perception). This likely accounts for CBC's contribution to cannabis's analgesic effects. CBC may also inhibit endocannabinoid reuptake, increasing anandamide levels.
¶ Summary: Structural Comparison Table
| Cannabinoid | Formula | MW (g/mol) | Ring System | Side Chain | Key Structural Feature | CB1 Affinity |
|---|---|---|---|---|---|---|
| Delta-9-THC | C21H30O2 | 314.47 | Closed (tricyclic) | Pentyl (C5) | Double bond at C9 | High (Ki 10-40 nM) |
| Delta-8-THC | C21H30O2 | 314.47 | Closed (tricyclic) | Pentyl (C5) | Double bond at C8 | Moderate (slightly lower) |
| THCA | C22H30O4 | 358.48 | Closed + COOH | Pentyl (C5) | Carboxyl group at C2 | Negligible |
| THCV | C19H26O2 | 286.41 | Closed (tricyclic) | Propyl (C3) | Shorter side chain | Dose-dependent (antagonist/agonist) |
| CBD | C21H30O2 | 314.47 | Open (bicyclic) | Pentyl (C5) | Open ring; no pyran bridge | Very low (NAM at CB1) |
| CBDA | C22H30O4 | 358.48 | Open + COOH | Pentyl (C5) | Open ring + carboxyl group | Negligible |
| CBG | C21H32O2 | 316.48 | Open (bicyclic) | Pentyl (C5) | Parent cannabinoid; no cyclization | Weak |
| CBN | C21H26O2 | 310.44 | Fully aromatic | Pentyl (C5) | Oxidized THC; 3 aromatic rings | Low (~10% of THC) |
| CBC | C21H30O2 | 314.47 | Closed (tricyclic) | Pentyl (C5) | Different ring orientation than THC | Very low |
¶ Biosynthesis Pathway: How Cannabis Produces Cannabinoids
Cannabinoids are not absorbed from the soil -- they are synthesized de novo by the cannabis plant through a well-characterized enzymatic pathway. Understanding this pathway explains why different strains produce different cannabinoid ratios and why the plant's cannabinoid profile changes over its life cycle.
¶ The Biosynthetic Pathway
Step 1: Formation of Olivetolic Acid (OA)
──────────────────────────────────────────
Hexanoyl-CoA + 3 × Malonyl-CoA
──(Olivetolic Acid Cyclase, OAC)──>
Olivetolic Acid (C11H14O3)
Step 2: Formation of CBGA (the "mother cannabinoid")
─────────────────────────────────────────────────────
Olivetolic Acid + Geranyl Pyrophosphate (GPP, C10H17O7P2-)
──(Cannabigerolic Acid Synthase, PT enzyme)──>
CBGA (C22H32O4) + PPi (pyrophosphate)
Step 3: Branching into individual cannabinoid acids
────────────────────────────────────────────────────
CBGA is the branch point for all major cannabinoids:
CBGA ──(THCA Synthase)──> THCA (C22H30O4)
CBGA ──(CBDA Synthase)──> CBDA (C22H30O4)
CBGA ──(CBCA Synthase)──> CBCA (C22H30O4)
CBGA ──(CBGA Synthase)──> CBGA (remains as CBGA)
Step 4: Decarboxylation (post-harvest, via heat or time)
─────────────────────────────────────────────────────────
THCA ──(heat)──> THC + CO2
CBDA ──(heat)──> CBD + CO2
CBCA ──(heat)──> CBC + CO2
CBGA ──(heat)──> CBG + CO2
¶ Enzymatic Details
THCA Synthase is a flavin adenine dinucleotide (FAD)-dependent oxidoreductase that catalyzes the oxidative cyclization of CBGA to THCA. The enzyme uses molecular oxygen to create the closed pyran ring structure characteristic of THC. It is located primarily in the glandular trichomes (the resin-producing hairs on cannabis flowers and sugar leaves).
CBDA Synthase is a similar FAD-dependent enzyme that catalyzes a different cyclization of CBGA, producing the open-ring structure of CBDA instead of the closed ring of THCA.
CBCA Synthase catalyzes yet another cyclization pathway, producing CBCA.
The critical point is that these enzymes compete for the same substrate (CBGA). The relative amounts of each enzyme expressed by a given plant determine its cannabinoid profile.
¶ Genetic Basis for Strain Differences
The genes encoding THCA synthase, CBDA synthase, and CBCA synthase are located at a single genetic locus on the cannabis genome. A cannabis plant inherits two alleles at this locus (one from each parent), and the combination determines its chemotype:
| Chemotype | Genotype | Cannabinoid Profile | Description |
|---|---|---|---|
| Type I | THCA/THCA (homozygous) | THC >20%, CBD <1% | THC-dominant; most recreational strains |
| Type II | THCA/CBDA (heterozygous) | THC ~10%, CBD ~10% | Balanced THC:CBD; "50/50" strains |
| Type III | CBDA/CBDA (homozygous) | CBD >10%, THC <1% | CBD-dominant; hemp and medical CBD strains |
| Type IV | CBGA-dominant | CBG >10% | CBG-dominant; emerging chemotype |
| Type V | Cannabinoid-null | Negligible cannabinoids | Non-cannabinoid producing (fiber hemp) |
This genetic model, first proposed by Ernest Small and later confirmed by molecular genetics, explains why crossing two Type I (THC-dominant) plants produces THC-dominant offspring, while crossing a Type I with a Type III produces Type II (balanced) offspring in the first generation. The F2 generation (seeds from Type II plants) will segregate in a classic 1:2:1 ratio: 25% Type I, 50% Type II, 25% Type III.
¶ Environmental and Developmental Influences
Beyond genetics, several factors influence cannabinoid production:
- Trichome maturity: Cannabinoid synthesis peaks when glandular trichomes transition from clear to cloudy/amber. Harvesting too early yields lower cannabinoid concentrations; harvesting too late allows more degradation to CBN.
- Light spectrum and intensity: UV-B radiation stimulates cannabinoid production as a protective response. This is one hypothesis for why high-altitude, high-UV cannabis (e.g., from Afghanistan or Morocco) tends to be more potent.
- Temperature: Optimal cannabinoid synthesis occurs at 20-30 degrees C (68-86 degrees F). Extreme heat or cold reduces production.
- Nutrient stress: Moderate nutrient stress can increase trichome production (and thus cannabinoid content) as a defense response, though severe stress reduces overall plant health and yield.
- Plant sex: Female plants produce significantly more trichomes (and therefore cannabinoids) than males. Unpollinated females ("sinsemilla") produce the highest concentrations.
Figure 3: The cannabinoid biosynthesis pathway from hexanoyl-CoA to major cannabinoids.
¶ How Each Cannabinoid Affects the Brain
¶ THC (Delta-9-Tetrahydrocannabinol)
Primary receptor targets:
- CB1 (Gi/o-coupled): Primary site of psychoactive action; high-affinity partial agonist
- CB2 (Gi/o-coupled): Lower affinity than CB1; contributes to anti-inflammatory effects
- 5-HT3A: Serotonin receptor; may contribute to anti-nausea effects
- GPR55: Orphan receptor; possible role in bone metabolism
- PPAR-gamma: Nuclear receptor; gene regulation, metabolism
- TRPV1: Vanilloid receptor; pain, temperature regulation
Neurotransmitter effects in the brain:
-
Dopamine: THC increases dopamine release in the nucleus accumbens (the brain's reward center) by inhibiting GABAergic interneurons in the ventral tegmental area (VTA). Normally, GABA interneurons suppress dopamine neuron firing. THC's activation of CB1 receptors on these GABA neurons reduces GABA release ("disinhibition"), allowing dopamine neurons to fire more freely. This dopamine surge is what produces euphoria and is a mechanism shared with other rewarding stimuli.
-
GABA: THC reduces GABA release in multiple brain regions via CB1 presynaptic inhibition. This contributes to reduced anxiety at low doses (less GABA-mediated inhibition in the amygdala) but can increase anxiety at high doses (disruption of normal inhibitory circuits).
-
Glutamate: THC inhibits glutamate release in the hippocampus via CB1 receptors on glutamatergic terminals. This impairs long-term potentiation (LTP), the cellular mechanism underlying memory formation, explaining THC's well-documented short-term memory impairment.
-
Serotonin: THC's interaction with 5-HT3A receptors may contribute to its antiemetic effects. The relationship between THC and serotonin systems is complex and dose-dependent.
Blood-brain barrier (BBB) crossing: THC is highly lipophilic (fat-soluble), allowing it to cross the BBB rapidly via passive diffusion. After inhalation, THC reaches the brain within seconds to minutes. Its lipophilicity also means it distributes into fatty tissues throughout the body and has a large volume of distribution.
Subjective effects tied to mechanism:
- Euphoria and reward: Dopamine release in nucleus accumbens
- Short-term memory impairment: Glutamate inhibition in hippocampus
- Increased appetite: CB1 activation in hypothalamus
- Altered time perception: CB1 effects in the basal ganglia and cerebellum
- Reduced pain: CB1 activation in periaqueductal gray (PAG) and spinal cord
- Anxiety/paranoia (high dose): Amygdala CB1 overactivation, GABA disruption
¶ CBD (Cannabidiol)
Primary receptor targets:
- CB1 (negative allosteric modulator): Reduces THC's efficacy at CB1
- 5-HT1A (agonist): Serotonin receptor; anti-anxiety, anti-nausea
- TRPV1 (agonist): Vanilloid receptor; pain, inflammation
- GPR55 (antagonist): May contribute to anti-cancer and bone effects
- PPAR-gamma (agonist): Anti-inflammatory, neuroprotective
- FAAH (inhibitor): Increases anandamide levels
Neurotransmitter effects:
-
Serotonin: CBD's agonism at 5-HT1A receptors is one of its most well-characterized actions. 5-HT1A activation in the raphe nuclei and amygdala reduces anxiety-related signaling. This mechanism is similar to how buspirone (an anti-anxiety medication) works, although CBD's affinity is lower.
-
Anandamide: By inhibiting FAAH, CBD increases the levels of the body's own endocannabinoid anandamide. Elevated anandamide may contribute to CBD's anxiolytic and antidepressant effects. This is significant because it means CBD partially works by enhancing the body's own ECS function rather than directly activating receptors.
-
Adenosine: CBD may inhibit the reuptake of adenosine (a neuromodulator that promotes sleep and suppresses arousal), contributing to its calming effects.
-
GABA: CBD has complex effects on GABA signaling. At some synapses, it enhances GABA activity (contributing to anti-anxiety and anticonvulsant effects); at others, it may reduce it. This bidirectional modulation may be why CBD can be calming without being strongly sedating.
BBB crossing: CBD crosses the BBB, though its complex pharmacology means its brain effects are less about direct receptor activation and more about modulating existing signaling systems. CBD has lower brain penetration than THC, but its effects on multiple targets create a broad modulatory influence.
Subjective effects tied to mechanism:
- Reduced anxiety: 5-HT1A agonism, increased anandamide
- Anti-seizure: Multiple mechanisms including TRPV1, GPR55, adenosine
- Reduced inflammation: PPAR-gamma activation, TRPV1
- Counteracting THC effects: CB1 negative allosteric modulation
- General sense of calm without sedation: Multi-target modulation
¶ CBG (Cannabigerol)
Primary receptor targets:
- CB1 (weak partial agonist): Low affinity
- CB2 (weak partial agonist): Slightly higher affinity than at CB1
- Alpha-2 adrenergic receptor (agonist): Pain modulation, anxiety
- 5-HT1A (antagonist): May modulate serotonin signaling
- TRPA1 (agonist): Pain, inflammation
Neurotransmitter effects:
CBG's effects on brain neurotransmitters are less well-studied than THC or CBD. Its alpha-2 adrenergic agonism may reduce norepinephrine release, producing calming effects. Its 5-HT1A antagonism (opposite to CBD's agonism) may have complex effects on serotonin signaling that are not yet fully understood.
BBB crossing: CBG crosses the BBB but with lower efficiency than THC due to its different structure. Its brain effects are likely modest compared to THC or CBD.
¶ CBN (Cannabinol)
Primary receptor targets:
- CB1 (weak partial agonist): Approximately 10% of THC's affinity
- CB2 (agonist): Moderate affinity; may contribute to immune effects
- TRPA1 (agonist): Pain, inflammation
- TRPV2 (agonist): Temperature regulation, immune function
Neurotransmitter effects:
CBN's weak CB1 activity produces mild psychoactive effects. Its interaction with TRP channels may contribute to pain modulation. The purported sedative effects of CBN have not been robustly demonstrated in controlled studies, and the sedation commonly attributed to CBN may actually result from combinations of CBN with residual THC and sedating terpenes (myrcene, linalool) in aged cannabis.
BBB crossing: CBN crosses the BBB due to its lipophilicity, but its lower CB1 affinity means brain effects are milder than THC.
¶ CBC (Cannabichromene)
Primary receptor targets:
- TRPV1 (agonist): Significant activity; pain, inflammation
- TRPA1 (agonist): Pain, itch sensation
- CB2 (weak agonist): Immune modulation
- CB1 (negligible): Non-psychoactive
- Endocannabinoid reuptake inhibition: May increase anandamide levels
Neurotransmitter effects:
CBC's TRPV1 agonism can initially produce a sensation of warmth or mild irritation, followed by desensitization of the receptor (which reduces pain signaling). Its potential to inhibit endocannabinoid reuptake means CBC may indirectly enhance anandamide signaling, contributing to mood-lifting and anti-anxiety effects.
BBB crossing: CBC crosses the BBB but its primary effects may be peripheral (TRPV1 on sensory neurons outside the brain).
¶ THCV (Tetrahydrocannabivarin)
Primary receptor targets:
- CB1: Antagonist at low doses; agonist at high doses (unique dose-dependent switch)
- CB2 (agonist): Moderate affinity
- 5-HT1A (agonist): May contribute to anti-anxiety effects
- TRPV1 (agonist): Pain modulation
Neurotransmitter effects:
At low doses, THCV's CB1 antagonism blocks the effects of anandamide and THC at CB1 receptors. This explains why THCV can suppress appetite (CB1 activation in the hypothalamus normally stimulates appetite) and potentially reduce anxiety (by blocking excessive CB1 activation). At high doses, THCV activates CB1 directly, producing clear, energizing psychoactive effects distinct from THC's more sedating profile.
BBB crossing: THCV's shorter propyl side chain makes it slightly less lipophilic than THC, but it still crosses the BBB effectively.
¶ THCA and CBDA (Acidic Cannabinoids)
Primary receptor targets:
- THCA: Does not bind CB1; may interact with COX-1/COX-2 (like NSAIDs), TRPV1, and TRPV2
- CBDA: High affinity for 5-HT1A (potentially higher than CBD); may activate TRPV1
Neurotransmitter effects:
CBDA's potent 5-HT1A agonism in the enteric nervous system (gut) may explain its strong anti-nausea effects -- the gut contains more serotonin receptors than the brain. THCA's COX inhibition may reduce prostaglandin production, contributing to anti-inflammatory effects similar to ibuprofen.
BBB crossing: The carboxyl group significantly reduces BBB penetration. Acidic cannabinoids primarily exert effects peripherally (outside the brain), which is why they are non-psychoactive. Some may cross the BBB in small amounts, but not enough to produce intoxication.
¶ Delta-8-THC
Primary receptor targets:
- CB1 (partial agonist): Similar to Delta-9-THC but lower affinity
- CB2 (partial agonist): Similar profile to Delta-9-THC
Neurotransmitter effects:
Delta-8-THC produces similar neurotransmitter changes as Delta-9-THC (dopamine release in nucleus accumbens, glutamate inhibition in hippocampus, GABA modulation) but to a lesser degree. The reduced CB1 affinity translates to a lower ceiling on all effects -- less euphoria but also less anxiety and paranoia.
BBB crossing: Crosses the BBB readily due to high lipophilicity.
¶ Decarboxylation Chemistry
¶ The Chemical Reaction
Decarboxylation is a thermal decomposition reaction in which a carboxyl group (-COOH) is removed from a molecule, releasing carbon dioxide (CO2). For cannabis cannabinoids, this converts the acidic, non-psychoactive forms into their active, neutral forms:
THCA (C22H30O4, MW 358.48) ──(heat)──> THC (C21H30O2, MW 314.47) + CO2 (MW 44.01)
CBDA (C22H30O4, MW 358.48) ──(heat)──> CBD (C21H30O2, MW 314.47) + CO2 (MW 44.01)
CBGA (C22H32O4, MW 360.48) ──(heat)──> CBG (C21H32O2, MW 316.48) + CO2 (MW 44.01)
CBCA (C22H30O4, MW 358.48) ──(heat)──> CBC (C21H30O2, MW 314.47) + CO2 (MW 44.01)
The reaction mechanism involves thermal energy breaking the carbon-carbon bond between the aromatic ring and the carboxyl group. The carboxyl group leaves as CO2 gas, and the remaining hydrogen on the ring rearranges to form the neutral cannabinoid.
¶ Reaction Kinetics
Decarboxylation follows first-order reaction kinetics, meaning the rate of conversion at any given moment is proportional to the amount of remaining acidic cannabinoid. The reaction rate increases exponentially with temperature (following the Arrhenius equation).
The rate constant k at a given temperature determines how quickly decarboxylation proceeds:
Conversion percentage = (1 - e^(-kt)) × 100
Where t is time and k is the temperature-dependent rate constant.
Measured decarboxylation rates for THCA:
| Temperature | Rate Constant (k, min^-1) | Time to 50% conversion | Time to 90% conversion | Time to ~100% conversion |
|---|---|---|---|---|
| 220°F (104°C) | ~0.015 | ~46 min | ~153 min | ~230 min |
| 230°F (110°C) | ~0.025 | ~28 min | ~92 min | ~140 min |
| 240°F (115°C) | ~0.040 | ~17 min | ~58 min | ~85 min |
| 250°F (121°C) | ~0.065 | ~11 min | ~35 min | ~55 min |
| 265°F (130°C) | ~0.110 | ~6 min | ~21 min | ~32 min |
| 300°F (149°C) | ~0.300 | ~2 min | ~8 min | ~12 min |
Note: These values are approximate and vary based on moisture content, plant material density, and oven calibration. The values above represent decarboxylation in an oven environment. In practice, most home users aim for 240°F (115°C) for 25-30 minutes as a good balance between complete decarboxylation and terpene preservation.
¶ Decarboxylation Temperature/Time Chart for Home Use
| Temperature | Time | Conversion Efficiency | Terpene Preservation | Recommended For |
|---|---|---|---|---|
| 220°F (104°C) | 30-40 min | 60-75% | Excellent | Raw juice users; maximum terpene retention |
| 230°F (110°C) | 25-35 min | 75-85% | Very good | Tinctures; topicals |
| 240°F (115°C) | 20-30 min | 85-95% | Good | Edibles (recommended); general use |
| 250°F (121°C) | 15-25 min | 90-97% | Moderate | When speed is prioritized over terpenes |
| 265°F (130°C) | 10-15 min | 95%+ | Poor | Vaporizer prep; quick decarb |
| 300°F (149°C) | 10-15 min | Near-complete | Very poor | Not recommended; significant cannabinoid degradation possible |
¶ Why Edibles MUST Use Decarbed Cannabis
When cannabis is smoked or vaporized, the heat of combustion (smoking: 900-1200 degrees F / 482-649 degrees C at the cherry) or vaporization (350-430 degrees F / 177-221 degrees C) instantly decarboxylates the cannabinoids before they enter the lungs. The user inhales active THC or CBD.
When cannabis is consumed orally without decarboxylation, the acidic cannabinoids pass through the digestive system largely unchanged. THCA does not bind to CB1 receptors, so eating raw cannabis flower will not produce psychoactive effects. While THCA and CBDA may have their own therapeutic properties, they will not produce the effects associated with THC or CBD.
For edibles to work, the cannabis must first be decarboxylated to convert THCA to THC (or CBDA to CBD). This is typically done by baking the ground flower in an oven before infusing it into butter, oil, or another fat.
Formula for calculating activated THC in flower: Total available THC = (THCA% × 0.877) + Delta-9-THC%. The 0.877 factor accounts for the mass lost as CO2 during decarboxylation (44.01 / 358.48 = 0.123 mass lost; 1 - 0.123 = 0.877 remaining).
¶ How Decarboxylation Affects Terpenes
Terpenes are volatile aromatic compounds that begin to evaporate at temperatures well below those needed for complete decarboxylation. This creates a trade-off between maximizing cannabinoid activation and preserving terpenes.
| Terpene | Boiling Point | Fate During Decarboxylation |
|---|---|---|
| Myrcene | 167°C (333°F) | Partially lost at higher decarb temps |
| Pinene | 155-165°C (311-329°F) | Significantly lost above 240°F |
| Limonene | 176°C (349°F) | Partially lost at higher decarb temps |
| Caryophyllene | 160°C (320°F) | Partially lost |
| Linalool | 198°C (388°F) | Moderate loss |
| Terpinolene | 183°C (361°F) | Partially lost |
| Humulene | ~198°C (388°F) | Moderate loss |
| Bisabolol | 154°C (309°F) | Significant loss above 220°F |
Practical implications: Users who want to preserve terpenes during decarboxylation should use the lowest effective temperature for the longest time (e.g., 220-230°F for 30-40 minutes). For maximum cannabinoid conversion where terpenes are less important (e.g., edibles where additional flavoring will be added), higher temperatures (240-250°F) are acceptable.
Some users employ a two-stage decarboxylation: a lower-temperature first stage to preserve volatile terpenes, followed by a higher-temperature stage for complete decarboxylation. Others decarb and then separately add back a terpene blend after infusion.
¶ Best Practices for Home Decarboxylation
- Grind coarsely: Break flower into pea-sized pieces. Too fine = burns; too coarse = uneven decarb.
- Use an oven thermometer: Oven dials are often inaccurate by 10-25 degrees F.
- Spread evenly on parchment-lined baking sheet: Ensures uniform heat exposure.
- Cover loosely with foil: Reduces terpene loss while allowing CO2 to escape.
- Stir halfway through: Promotes even heating.
- Color as indicator: Properly decarbed cannabis turns from green to light brown/tan. Dark brown or black indicates over-decarboxylation (cannabinoid degradation).
¶ Pharmacokinetics: How the Body Processes Cannabinoids
Pharmacokinetics describes what the body does to a drug -- how it is absorbed, distributed, metabolized, and eliminated (ADME). Cannabinoids have complex pharmacokinetics that vary dramatically depending on the route of administration.
¶ Absorption
| Route | Onset | Peak Blood Levels | Bioavailability | Key Mechanisms |
|---|---|---|---|---|
| Inhalation (smoking) | 1-5 min | 3-10 min | ~25-31% (highly variable) | Alveolar absorption; bypasses first-pass; pyrolysis destroys some THC |
| Inhalation (vaporizing) | 1-5 min | 3-10 min | ~30-46% | Alveolar absorption; no combustion; more efficient than smoking |
| Oral (edibles/capsules) | 30-120 min | 1-4 hours | ~4-20% (highly variable) | GI absorption; extensive first-pass metabolism; food enhances absorption |
| Sublingual (tinctures/sprays) | 15-45 min | 30-90 min | ~13-35% | Partial absorption through oral mucosa; partial swallowed and first-pass |
| Transdermal (patches) | 30-60 min | 2-8 hours | Variable (designed for sustained delivery) | Through skin layers into capillaries; bypasses first-pass |
| Rectal (suppositories) | 15-45 min | 1-3 hours | ~50%+ (estimated) | Rectal mucosa absorption; ~50% bypasses first-pass via inferior hemorrhoidal veins |
| Intravenous | Immediate | Immediate | 100% | Research setting only |
Key absorption factors:
- Fat content: Cannabinoids are highly lipophilic. Consuming them with dietary fat significantly increases oral bioavailability. One study showed a 2.5- to 3-fold increase in THC absorption when cannabis was consumed with a high-fat meal compared to fasting.
- Particle size (for inhalation): Smaller particles reach deeper into the lungs, increasing absorption. Larger particles deposit in the mouth and throat and are swallowed.
- Holding smoke/vapor in lungs: Studies show that holding breath beyond 3-5 seconds provides negligible additional absorption. Most THC is absorbed during the initial inhalation.
¶ Distribution
Once absorbed, cannabinoids distribute throughout the body according to their lipophilicity (fat solubility):
- Volume of distribution (Vd): THC has an extremely large Vd (~10 L/kg), meaning it distributes far beyond the blood into tissues throughout the body. This is one of the largest Vd values of any drug.
- Fat storage: THC and its metabolites accumulate in adipose tissue (body fat), where they can persist for days to weeks. This is why cannabinoids can be detected in drug tests long after the psychoactive effects have worn out.
- Blood-brain barrier: THC crosses the BBB rapidly (within seconds to minutes of inhalation) via passive diffusion due to its high lipophilicity.
- Protein binding: THC is approximately 97% bound to plasma proteins (primarily lipoproteins and albumin), meaning only ~3% is "free" and pharmacologically active at any given time.
- Redistribution: After initial brain uptake, THC redistributes from the brain to fatty tissues, which is why the psychoactive effects of a single dose peak quickly and then decline even though the drug is still present in the body.
¶ Metabolism
Cannabinoids are primarily metabolized by the cytochrome P450 (CYP450) enzyme system in the liver.
THC metabolism pathway:
THC (C21H30O2)
│
├──(CYP2C9, ~75%)──> 11-OH-THC (11-hydroxy-THC)
│ │
│ │ 11-OH-THC is MORE psychoactive than THC
│ │ and crosses the BBB even more readily
│ │
│ ├──(CYP3A4, CYP2C9)──> THC-COOH
│ │ │
│ │ │ THC-COOH is NON-psychoactive
│ │ │ This is what drug tests detect
│ │ │
│ │ └──> Glucuronidation (UGT enzymes)
│ │ THC-COOH-glucuronide (water-soluble)
│ │ Excreted in urine and feces
│ │
│ └──> Other minor metabolites
│
└──(CYP3A4, ~15%)──> THC-COOH (direct, minor pathway)
Key metabolic points:
-
11-OH-THC (11-hydroxy-THC): This metabolite is equally or more psychoactive than THC itself and crosses the BBB more readily. When THC is consumed orally (edibles), the first-pass metabolism in the liver converts a significant portion of THC to 11-OH-THC before it reaches systemic circulation. This is a major reason why edibles feel different from inhaled THC -- the user is experiencing a combination of THC and 11-OH-THC rather than THC alone.
-
THC-COOH: This is the primary inactive metabolite. It is not psychoactive but is the compound detected in urine drug tests. THC-COOH is conjugated with glucuronic acid (by UGT enzymes) to make it water-soluble for excretion.
CBD metabolism:
CBD ──(CYP3A4, CYP2C19)──> 7-OH-CBD ──> 7-COOH-CBD ──> Glucuronidation ──> Excretion
CBD undergoes extensive first-pass metabolism. When taken orally, only about 6% of the administered dose reaches systemic circulation unchanged. CBD is also a potent inhibitor of CYP2D6, CYP3A4, and CYP2C19, which is the basis for its many drug interactions.
¶ Elimination
| Parameter | THC | 11-OH-THC | THC-COOH | CBD |
|---|---|---|---|---|
| Initial half-life (distribution) | ~5-10 min | Similar | N/A | N/A |
| Terminal half-life (elimination) | 25-36 hours (occasional users); up to 5-8 days (chronic users) | ~40 min | 3-4 days | 18-32 hours |
| Primary excretion | Feces (~65%), Urine (~30%) | Further metabolized to THC-COOH | Urine (as glucuronide conjugate) | Feces (primary), Urine |
| Time to clear from blood | 1-2 days (occasional); up to 7 days (chronic) | Hours | Weeks | 2-5 days |
Detection windows for drug testing:
| Test Type | Detection Window (occasional user) | Detection Window (chronic daily user) | What It Detects |
|---|---|---|---|
| Urine | 3-7 days | 30-90+ days | THC-COOH (inactive metabolite) |
| Blood | 1-2 days | Up to 7 days | THC and 11-OH-THC (active compounds) |
| Saliva | 24-72 hours | Up to 72 hours | THC (parent compound) |
| Hair | Up to 90 days | Up to 90 days | THC-COOH incorporated into hair shaft |
Note: Detection windows are highly variable and depend on body fat percentage, metabolism rate, frequency of use, potency of cannabis consumed, and the sensitivity of the test. The commonly cited "30 days" for urine testing is a general guideline, not a rule. Heavy chronic users with high body fat may test positive for 90+ days, while single-use occasional users may clear in 3-5 days.
¶ Drug Interactions
Cannabinoids, particularly CBD and THC, interact with the cytochrome P450 (CYP450) enzyme system, which is responsible for metabolizing approximately 70-80% of all prescription medications. This creates the potential for clinically significant drug interactions.
¶ CYP450 Enzymes Affected by Cannabinoids
| Enzyme | Affected By | Clinical Significance |
|---|---|---|
| CYP3A4 | Inhibited by CBD and THC | Most important; metabolizes ~50% of all drugs |
| CYP2C9 | Inhibited by CBD; also metabolizes THC | Affects warfarin, NSAIDs, some antiepileptics |
| CYP2C19 | Inhibited by CBD | Affects SSRIs, PPIs, clopidogrel |
| CYP2D6 | Inhibited by CBD | Affects many antidepressants, antipsychotics, beta-blockers |
| CYP1A2 | Inhibited by CBD; induced by smoke (not cannabinoids) | Cannabis smoke (like tobacco smoke) can induce this enzyme |
| UGT enzymes | CBD inhibits UGT1A9, UGT2B7 | Affects morphine, acetaminophen metabolism |
¶ Expanded Drug Interaction Table
| Medication Class | Specific Medications | Interaction Mechanism | Clinical Effect | Risk Level |
|---|---|---|---|---|
| Anticoagulants | Warfarin (Coumadin) | CBD inhibits CYP2C9, which metabolizes warfarin | Increased warfarin levels; increased bleeding risk; elevated INR | High |
| Antiplatelet agents | Clopidogrel (Plavix) | CBD inhibits CYP2C19, which activates clopidogrel | Reduced clopidogrel activation; decreased antiplatelet effect | High |
| Antiepileptics | Clobazam (Onfi) | CBD inhibits CYP2C19, increasing N-desmethylclobazam | Increased sedation; increased active metabolite (often requires dose reduction of clobazam) | High |
| Antiepileptics | Valproate (Depakote) | Both CBD and valproate can elevate liver enzymes | Increased risk of hepatotoxicity; requires liver function monitoring | High |
| Antiepileptics | Carbamazepine, Phenytoin | CYP3A4/CYP2C9 interactions; bidirectional | Altered levels of both cannabinoid and antiepileptic | Moderate-High |
| SSRIs | Fluoxetine, Sertraline, Citalopram, Escitalopram | CBD inhibits CYP2D6 and CYP2C19 | Increased SSRI blood levels; risk of serotonin syndrome (rare) | Moderate |
| SNRIs | Venlafaxine, Duloxetine | CBD inhibits CYP2D6 | Increased SNRI levels | Moderate |
| Tricyclic antidepressants | Amitriptyline, Nortriptyline | CBD inhibits CYP2D6 | Increased TCA levels; cardiac conduction effects | Moderate-High |
| Benzodiazepines | Alprazolam, Diazepam, Lorazepam | CBD inhibits CYP3A4 (alprazolam, diazepam); additive sedation | Enhanced sedation; increased benzodiazepine levels | Moderate |
| Opioids | Morphine, Oxycodone, Fentanyl, Codeine | THC + opioid: additive CNS depression; CBD inhibits CYP3A4 (fentanyl, oxycodone) and CYP2D6 (codeine activation) | Enhanced sedation and respiratory depression risk; altered opioid metabolism | High |
| Statins | Atorvastatin, Simvastatin, Lovastatin | CBD inhibits CYP3A4 | Increased statin levels; risk of myopathy/rhabdomyolysis | Moderate |
| Statins | Rosuvastatin, Pravastatin | Minimal CYP metabolism | Lower interaction risk | Low |
| Calcium channel blockers | Amlodipine, Diltiazem, Verapamil | CBD inhibits CYP3A4 | Increased blood pressure medication levels; hypotension risk | Moderate |
| Beta-blockers | Metoprolol, Propranolol, Carvedilol | CBD inhibits CYP2D6 | Increased beta-blocker levels; bradycardia, hypotension | Moderate |
| Immunosuppressants | Tacrolimus, Cyclosporine | CBD inhibits CYP3A4 | Dramatically increased immunosuppressant levels; toxicity risk | High |
| PPIs | Omeprazole, Esomeprazole | CBD inhibits CYP2C19 | Increased PPI levels; usually not clinically significant | Low-Moderate |
| Antifungals | Ketoconazole, Fluconazole | These drugs inhibit CYP enzymes that metabolize cannabinoids | Increased cannabinoid levels (opposite direction) | Moderate |
| Macrolide antibiotics | Clarithromycin, Erythromycin | Inhibit CYP3A4 | Increased cannabinoid levels | Moderate |
| HIV antiretrovirals | Ritonavir, Atazanavir | Potent CYP3A4 inhibitors | Dramatically increased cannabinoid levels | High |
| Sedating antihistamines | Diphenhydramine, Hydroxyzine | Additive CNS depression with THC/CBD | Enhanced sedation | Low-Moderate |
| Acetaminophen (Paracetamol) | Tylenol | CBD inhibits UGT enzymes; both can affect liver at high doses | Potential for increased acetaminophen levels; liver stress | Low-Moderate |
| NSAIDs | Ibuprofen, Naproxen | CBD inhibits CYP2C9 | Slightly increased NSAID levels; usually not clinically significant | Low |
| Stimulants | Amphetamine, Methylphenidate | THC may counteract therapeutic effects; complex interaction | Reduced stimulant efficacy; unpredictable effects | Moderate |
| Diabetes medications | Metformin, Insulin | THC affects blood sugar; THCV may improve insulin sensitivity | Variable effects on blood glucose; monitoring recommended | Low-Moderate |
¶ The "Grapefruit Test"
Many medications carry a grapefruit warning because compounds in grapefruit (furanocoumarins) inhibit CYP3A4. CBD inhibits many of the same enzymes. As a general screening tool:
If a medication carries a grapefruit warning, CBD is likely to interact with it in a similar way.
This is not a substitute for professional medical consultation but serves as a useful red flag for patients considering cannabinoid use alongside prescription medications.
¶ Smoking and CYP1A2 Induction
Importantly, cannabis smoke (like tobacco smoke) contains polycyclic aromatic hydrocarbons (PAHs) that induce (increase the activity of) CYP1A2. This means smoking cannabis can increase the metabolism of drugs processed by CYP1A2, potentially reducing their effectiveness:
- Clozapine (antipsychotic): Smoking may reduce blood levels by 20-40%
- Olanzapine (antipsychotic): Similar effect
- Theophylline (asthma): Reduced effectiveness
- Warfarin: CYP1A2 induction may increase R-warfarin metabolism (though S-warfarin, the more potent enantiomer, is metabolized by CYP2C9)
This effect is caused by smoke itself, not by cannabinoids. Vaporized or oral cannabinoids do not produce this induction effect.
¶ Tolerance and Dependence
¶ CB1 Receptor Downregulation
The primary mechanism of cannabis tolerance is CB1 receptor downregulation. When CB1 receptors are repeatedly activated by THC, the brain adapts through several interconnected processes:
-
Desensitization (minutes to hours): After THC activates a CB1 receptor, the receptor is phosphorylated by G protein-coupled receptor kinases (GRKs). This phosphorylation prevents the receptor from signaling, effectively "turning it off" even though it is still present on the cell surface.
-
Internalization (hours to days): Desensitized CB1 receptors are endocytosed (pulled inside the cell) into intracellular vesicles. They are no longer available on the cell surface to receive signals from endocannabinoids or THC.
-
Downregulation (days to weeks): If THC exposure continues, internalized CB1 receptors are degraded (broken down by lysosomes) rather than being recycled back to the surface. The total number of CB1 receptors in the brain decreases.
-
Reduced receptor expression (weeks): Chronic THC exposure may also reduce the gene expression of CB1 receptors, meaning the cell produces fewer new receptors to replace the ones being degraded.
Regional differences: CB1 downregulation is not uniform across the brain. Regions with the highest CB1 density show the most pronounced downregulation:
| Brain Region | CB1 Density | Tolerance Development |
|---|---|---|
| Basal ganglia | Very high | Rapid tolerance to motor effects |
| Cerebellum | Very high | Rapid tolerance to coordination effects |
| Hippocampus | High | Tolerance to memory impairment develops slowly |
| Nucleus accumbens | Moderate | Tolerance to euphoria develops relatively quickly |
| Brainstem | Very low | Minimal tolerance to respiratory effects (and minimal respiratory risk from THC alone) |
| Amygdala | Moderate | Tolerance to anxiety-reducing effects varies |
¶ Recovery Timeline
When THC exposure stops, CB1 receptors gradually recover through de novo synthesis (new receptor production) and recycling of internalized receptors:
| Time Since Last Use | CB1 Receptor Recovery | Subjective Effects |
|---|---|---|
| 12-24 hours | Beginning of desensitization reversal | Residual tolerance still present |
| 2 days | ~15-20% receptor recovery | Slight reduction in tolerance |
| 4 days | ~30-40% recovery | Noticeable tolerance reduction |
| 7 days | ~50-60% recovery | Significant tolerance reset |
| 14 days | ~70-80% recovery | Near-baseline sensitivity for most users |
| 21-28 days | ~90-95% recovery | Essentially full recovery in most brain regions |
| 4+ weeks | Full recovery | Complete tolerance reset |
Note: A landmark 2016 PET imaging study by d'Humières et al. (published in Neuropsychopharmacology) demonstrated that CB1 receptor density in chronic cannabis users returned to normal levels after approximately 4 weeks of abstinence. This study provided the first direct in-vivo evidence of CB1 receptor recovery in humans.
¶ Cannabis Use Disorder (CUD) Statistics
While cannabis has a lower dependence liability compared to many other substances (including alcohol, nicotine, and opioids), Cannabis Use Disorder is a recognized diagnosis in the DSM-5.
| Statistic | Value | Notes |
|---|---|---|
| Lifetime risk of dependence | ~9% of all users | Lower than alcohol (~15%), nicotine (~32%), heroin (~23%), cocaine (~21%) |
| Dependence among daily users | ~25-50% | Significantly higher with daily use, especially with high-potency products |
| Adolescent initiation risk | ~17% (1 in 6) for those who begin before age 18 | Developing brain more vulnerable |
| DSM-5 CUD criteria met | ~2.5% of US population (ages 12+) | Approximately 6-7 million people |
| Severity distribution | ~48% mild, ~33% moderate, ~19% severe | Most cases are mild to moderate |
| Withdrawal syndrome | ~40-50% of daily users experience some withdrawal symptoms upon cessation | Recognized in DSM-5 |
¶ Cannabis Withdrawal Syndrome
Cannabis withdrawal syndrome is characterized by a cluster of symptoms that typically begin 1-3 days after cessation, peak at days 2-6, and gradually resolve over 2-4 weeks:
| Symptom | Prevalence in Withdrawal | Typical Duration |
|---|---|---|
| Irritability/anger | Very common (~80%) | 1-3 weeks |
| Sleep difficulty/insomnia | Very common (~75%) | 1-4 weeks |
| Decreased appetite | Common (~60%) | 1-2 weeks |
| Restlessness | Common (~55%) | 1-2 weeks |
| Depressed mood | Common (~50%) | 1-3 weeks |
| Anxiety | Common (~45%) | 1-2 weeks |
| Abdominal pain/cramping | Moderate (~35%) | 3-10 days |
| Headache | Moderate (~30%) | 3-7 days |
| Sweating | Moderate (~25%) | 3-7 days |
| Tremor | Less common (~15%) | 3-5 days |
| Elevated temperature | Less common (~10%) | 2-5 days |
Withdrawal severity correlates with:
- Frequency and duration of use: Daily, multi-year users experience more severe withdrawal.
- Potency of cannabis used: Higher-THC products are associated with more significant withdrawal.
- Individual factors: Genetics, mental health status, and social support all influence withdrawal severity.
¶ Tolerance Management
For patients using cannabis medically, tolerance management is an important consideration:
- Tolerance breaks (T-breaks): A period of abstinence (typically 2-4 weeks) allows CB1 receptors to reset. Even shorter breaks (48-72 hours) can partially restore sensitivity.
- THC:CBD ratios: Products with higher CBD content may slow tolerance development, as CBD's negative allosteric modulation at CB1 may partially counteract the receptor downregulation caused by THC.
- Dose optimization: Using the minimum effective dose reduces the rate of tolerance development.
- Rotating consumption methods: Alternating between inhalation (rapid onset, short duration) and oral (slower onset, longer duration) may help reduce overall daily THC exposure while maintaining symptom relief.
¶ Major Cannabinoids
¶ THC (Delta-9-Tetrahydrocannabinol)
Chemical formula: C21H30O2
Molecular weight: 314.47 g/mol
IUPAC name: (6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol
Delta-9-tetrahydrocannabinol (THC) is the primary psychoactive compound in cannabis and the most extensively studied cannabinoid. It was first isolated and synthesized by Raphael Mechoulam and Yechiel Gaoni in 1964.
¶ Mechanism of Action
THC is a partial agonist at both CB1 and CB2 receptors, with significantly higher affinity for CB1. This partial agonism means THC activates these receptors but not to their maximum possible response, which helps explain why cannabis overdose fatalities from THC alone are essentially nonexistent -- CB1 receptors have a ceiling effect.
THC also interacts with:
- Serotonin receptors (5-HT3A)
- GPR55 (orphan receptor)
- PPAR-gamma (peroxisome proliferator-activated receptor gamma)
- TRPV1 (transient receptor potential vanilloid 1)
¶ Effects
| Category | Effects |
|---|---|
| Psychoactive | Euphoria, altered time perception, heightened sensory experience, relaxed cognition, short-term memory impairment |
| Physical | Increased heart rate, blood vessel dilation (red eyes), increased appetite, dry mouth, reduced intraocular pressure |
| Therapeutic (observed) | Pain relief, antiemetic (nausea reduction), appetite stimulation, muscle relaxant, sleep aid |
¶ Medical Uses and Research
FDA-approved THC-based medications include:
| Medication | Form | Approved Use |
|---|---|---|
| Marinol (dronabinol) | Synthetic THC capsule | Nausea/vomiting from chemotherapy; AIDS-related anorexia |
| Cesamet (nabilone) | Synthetic THC analog capsule | Chemotherapy-induced nausea (when other treatments fail) |
| Sativex (nabiximols) | THC:CBD oromucosal spray | Spasticity in multiple sclerosis (approved in 30+ countries) |
Research continues into THC's potential for chronic pain management, PTSD, and neurological conditions, though larger-scale clinical trials remain limited by regulatory restrictions in many jurisdictions.
For a critical look at common misconceptions and exaggerated claims about cannabis compounds, see [[/science/bro-science]].
¶ Potency Ranges
| Product Type | Typical THC Range | Notes |
|---|---|---|
| Traditional cannabis flower (1990s) | 2-4% | Historical baseline |
| Modern cannabis flower | 15-30% | Contemporary dispensary range |
| High-THC cultivars | 25-35% | Specialty/breed-optimized strains |
| Concentrates (shatter, wax) | 60-90% | Extraction-dependent |
| Distillate | 85-99% | Highly refined |
| Edibles (single serving) | 2.5-10 mg | Dosing by weight, not percentage |
¶ Side Effects and Adverse Reactions
Common side effects include dry mouth, red eyes, increased heart rate, short-term memory impairment, and coordination issues. Higher doses or individual sensitivity may produce:
- Anxiety or paranoia
- Dizziness or lightheadedness
- Nausea (at very high doses)
- Impaired driving ability (reaction time and motor coordination affected)
- In adolescents: potential impact on developing brain (research ongoing)
Caution: THC impairs psychomotor function. Operating vehicles or machinery under the influence is dangerous and illegal in most jurisdictions. Effects are dose-dependent and vary significantly between individuals based on tolerance, body chemistry, and consumption method.
¶ CBD (Cannabidiol)
Chemical formula: C21H30O2
Molecular weight: 314.47 g/mol
IUPAC name: 2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
Cannabidiol (CBD) is the second most abundant cannabinoid in most cannabis varieties and the most studied non-psychoactive cannabinoid. Unlike THC, CBD does not produce intoxicating effects and has minimal affinity for CB1 or CB2 receptors.
¶ Mechanism of Action
CBD operates through multiple pathways:
- Negative allosteric modulator of CB1: Alters the receptor's shape, reducing THC's binding efficiency (which is why CBD can moderate THC's psychoactive effects)
- 5-HT1A receptor agonist: Serotonin receptor interaction linked to anti-anxiety effects
- TRPV1 agonist: Vanilloid receptor involved in pain perception and inflammation
- GPR55 antagonist: May contribute to anti-cancer and bone-density effects
- FAAH inhibitor: Increases anandamide levels by preventing its breakdown
¶ Medical Uses and Research
| Application | Evidence Level | Notes |
|---|---|---|
| Epilepsy (Dravet/Lennox-Gastaut syndromes) | Strong (FDA-approved) | Epidiolex approved 2018; significant seizure reduction in clinical trials |
| Anxiety | Moderate | Multiple studies show reduced anxiety in social anxiety disorder and PTSD |
| Inflammation | Moderate | Preclinical and some clinical evidence; topical and systemic |
| Pain (neuropathic) | Moderate | Often studied in combination with THC (1:1 ratio) |
| Sleep | Limited-moderate | May improve sleep quality indirectly through anxiety/pain reduction |
| Psychosis | Emerging | Antipsychotic properties under investigation; may counteract THC-induced psychosis |
¶ THC:CBD Ratios
The ratio of THC to CBD significantly influences the user experience:
| Ratio | Experience | Common Use Cases |
|---|---|---|
| 20:1+ (THC-dominant) | Strongly psychoactive | Recreational; severe pain; insomnia |
| 10:1 | Psychoactive with mild CBD moderation | Experienced users seeking balanced effects |
| 5:1 | Moderate psychoactivity with noticeable CBD effects | Pain; anxiety; intermediate users |
| 2:1 | Mild psychoactivity, CBD-forward | Beginners; daytime use; anxiety |
| 1:1 | Balanced; reduced intoxication | Medical patients; spasticity; pain |
| 1:2 (CBD-dominant) | Minimal psychoactivity | Anxiety; inflammation; daytime function |
| 1:10+ (CBD-only) | Non-psychoactive | General wellness; epilepsy; pediatric use |
¶ CBG (Cannabigerol)
Chemical formula: C21H32O2
Molecular weight: 316.48 g/mol
Cannabigerol (CBG) is often called the "mother cannabinoid" because it is the precursor from which other cannabinoids are synthesized. In the living cannabis plant, cannabinoids begin as CBGA (cannabigerolic acid), which enzymes convert into THCA, CBDA, and CBCA. Most CBG is converted to other cannabinoids as the plant matures, leaving only trace amounts (typically under 1%) in mature flower.
¶ Properties and Research
| Property | Research Status |
|---|---|
| Antibacterial | Demonstrated activity against MRSA in preclinical studies |
| Anti-inflammatory | Shown in inflammatory bowel disease (IBD) models |
| Neuroprotective | Potential in Huntington's disease models |
| Intraocular pressure | Reduced IOP in glaucoma models (both CBG and CBGA) |
| Appetite stimulation | Increased feeding behavior in animal studies |
| Anti-cancer | Inhibited colon cancer cell growth in vitro |
CBG is non-psychoactive and generally well-tolerated. Breeders are developing high-CBG cultivars through selective breeding, and CBG products (oils, isolates, flower) are increasingly available in markets with legal cannabis.
Note: Because CBG concentrations in typical cannabis are very low, CBG products often require processing large quantities of plant material or using specially bred high-CBG cultivars, which can make CBG products more expensive than CBD equivalents.
¶ CBN (Cannabinol)
Chemical formula: C21H26O2
Molecular weight: 310.44 g/mol
Cannabinol (CBN) is a degradation product of THC. When THC is exposed to heat, light, or oxygen over time, it oxidizes and converts to CBN. This is why aged or improperly stored cannabis contains higher CBN levels. Historically, CBN was the first cannabinoid to be isolated (late 19th century), though its structure was not confirmed until the 1940s.
¶ Properties
| Property | Details |
|---|---|
| Psychoactivity | Mild -- approximately 10% as psychoactive as THC |
| Sedation | Most commonly associated effect; research is limited but growing |
| Appetite stimulation | Demonstrated in animal studies |
| Antibacterial | Activity against MRSA in preclinical research |
| Anti-convulsant | Some evidence in animal models |
| Bone growth | Potential stimulation of bone growth in rodent studies |
¶ Sleep Research
CBN is widely marketed as a sleep aid, but the scientific evidence remains limited. A 2021 study by Steep Hill Labs suggested CBN had sedative properties, though the study was small and not peer-reviewed. More rigorous research is needed. The sedative effect, if confirmed, may be partially attributable to the entourage effect -- CBN combined with residual THC and terpenes like myrcene and linalool, rather than CBN alone.
¶ CBC (Cannabichromene)
Chemical formula: C21H30O2
Molecular weight: 314.47 g/mol
Cannabichromene (CBC) is a non-psychoactive cannabinoid that is the third most common in many cannabis varieties. Like CBG and THC, it begins as CBGA and is synthesized by the enzyme CBCA synthase.
¶ Properties and Research
| Property | Research Status |
|---|---|
| Anti-inflammatory | Demonstrated in animal models; may contribute to cannabis's overall anti-inflammatory profile |
| Anti-depressant | Showed antidepressant-like effects in mouse models |
| Analgesic | Contributed to pain relief in combination with THC and CBD |
| Neurogenesis | Promoted growth of new brain cells in rodent studies |
| Anti-acne | Potent anti-inflammatory action on sebaceous glands |
| Non-psychoactive | Does not produce intoxication; does not bind strongly to CB1 |
CBC works synergistically with other cannabinoids, and its effects are most notable in the context of full-spectrum products rather than as an isolated compound.
¶ THCV (Tetrahydrocannabivarin)
Chemical formula: C19H26O2
Molecular weight: 286.41 g/mol
Tetrahydrocannabivarin (THCV) is a homologue of THC with a shorter side chain (propyl instead of pentyl). This structural difference produces notably different pharmacological effects.
¶ Unique Properties
| Property | Details |
|---|---|
| Appetite suppression | Unlike THC (which stimulates appetite), THCV suppresses it at lower doses -- earning the nickname "diet cannabinoid" |
| Blood sugar regulation | Improved pancreatic function and insulin sensitivity in preliminary studies |
| Energizing | Users report clear, stimulating effects rather than sedation |
| Dose-dependent psychoactivity | At low doses: CB1 antagonist (blocks THC); at high doses: CB1 agonist (psychoactive) |
| Bone health | Promoted bone cell growth in preclinical studies |
| Panic attacks | Potential to reduce panic attacks without affecting other emotions |
THCV is found in higher concentrations in African landrace sativa strains and certain specialized cultivars. It remains one of the rarer cannabinoids in commercial products.
¶ THCA and CBDA (Acidic Precursors)
| Cannabinoid | Formula | Decarboxylated Form |
|---|---|---|
| THCA (Tetrahydrocannabinolic acid) | C22H30O4 | THC (C21H30O2) + CO2 |
| CBDA (Cannabidiolic acid) | C22H30O4 | CBD (C21H30O2) + CO2 |
¶ What Are Acidic Cannabinoids?
In the living cannabis plant, cannabinoids exist primarily in their acidic forms. THCA, CBDA, CBGA, and CBCA are the raw, unprocessed precursors. These acidic cannabinoids are non-psychoactive -- consuming raw cannabis flower will not produce intoxication because THCA does not bind to CB1 receptors in its acidic form.
¶ Potential Therapeutic Properties
Research into acidic cannabinoids is early but promising:
- THCA: Potential anti-inflammatory, anti-nausea, and neuroprotective properties; may inhibit COX-1 and COX-2 enzymes (similar to NSAIDs)
- CBDA: Potent anti-nausea and anti-anxiety effects (some studies suggest CBDA may be more potent than CBD for nausea); potential anti-breast-cancer activity in vitro
- Raw cannabis consumption: Juicing raw cannabis leaves and flower provides acidic cannabinoids without psychoactive effects, though clinical evidence for benefits is limited
¶ Delta-8-THC
Chemical formula: C21H30O2 (isomer of Delta-9-THC)
Molecular weight: 314.47 g/mol
Delta-8-tetrahydrocannabinol is a structural isomer of Delta-9-THC. The double bond is located on the 8th carbon chain instead of the 9th, producing a compound with similar but notably milder effects.
¶ Key Characteristics
| Property | Details |
|---|---|
| Potency | Approximately 50-75% as potent as Delta-9-THC |
| Effects | Similar to THC but described as clearer, less anxiety-inducing, more functional |
| Side effects | Reduced anxiety and paranoia compared to Delta-9; still produces dry mouth, red eyes |
| Legal status | Gray area in many jurisdictions; often derived from hemp-derived CBD through chemical conversion |
¶ Production Concerns
Most Delta-8-THC on the market is semi-synthetic, produced by isomerizing CBD (extracted from hemp) using acids and solvents. This process raises several concerns:
- Residual solvents: Incomplete purification may leave acids and chemical byproducts in the final product
- Unknown byproducts: The isomerization process can produce various compounds that may not be tested for or disclosed
- Lack of regulation: In unregulated markets, products may contain inconsistent Delta-8 levels or contaminants
- Mislabeling: Studies have found significant discrepancies between labeled and actual Delta-8 content in commercial products
Caution: Consumers in jurisdictions where Delta-8 is legally available should seek products with third-party lab testing (Certificates of Analysis) that screen for residual solvents, heavy metals, and byproducts. The semi-synthetic production process distinguishes Delta-8 from naturally occurring cannabinoids.
¶ Minor and Emerging Cannabinoids
Beyond the major cannabinoids described above, dozens of additional cannabinoids have been identified. Research into these compounds is in early stages:
| Cannabinoid | Notable Properties | Research Status |
|---|---|---|
| CBL (Cannabicyclol) | Degradation product of CBC; minimal research | Very limited |
| CBT (Cannabicitran) | Degradation product; non-psychoactive | Very limited |
| THC-P | Binds to CB1 with significantly higher affinity than THC | Emerging; potency claims require verification |
| CBD-P | Propyl homologue of CBD | Very limited |
| CBN-C4 | Butyl homologue of CBN | Very limited |
| Delta-10-THC | Similar to Delta-8; also semi-synthetic | Limited; similar production concerns to Delta-8 |
| HHC (Hexahydrocannabinol) | Hydrogenated THC; more stable; semi-synthetic | Limited; legal status varies |
| CBGA | Parent cannabinoid; potential metabolic benefits | Early research |
¶ Cannabinoid Comparison Table
| Cannabinoid | Psychoactive | Primary Receptor Activity | Notable Properties | Typical Concentration in Flower |
|---|---|---|---|---|
| THC (Delta-9) | Yes (strong) | CB1/CB2 partial agonist | Pain relief, antiemetic, appetite stimulation | 10-30% |
| CBD | No | Indirect ECS modulation; 5-HT1A, TRPV1 | Anti-anxiety, anti-seizure, anti-inflammatory | 0.1-20%+ |
| CBG | No | Weak CB1/CB2 agonist | Antibacterial, neuroprotective, anti-inflammatory | <1% (typically) |
| CBN | Mild | CB1/CB2 weak agonist | Sedation, antibacterial, appetite stimulation | 0.1-1% (higher in aged cannabis) |
| CBC | No | TRPV1/TRPA1 agonist; weak CB2 | Anti-inflammatory, anti-depressant, analgesic | 0.1-1% |
| THCV | Dose-dependent | CB1 antagonist (low dose); agonist (high dose) | Appetite suppression, blood sugar regulation | <1% (higher in African landraces) |
| THCA | No | Does not bind CB1 | Anti-inflammatory, anti-nausea (raw form) | 10-25% (fresh flower) |
| CBDA | No | 5-HT1A agonist | Anti-nausea, anti-anxiety (raw form) | Variable (CBD-dominant strains) |
| Delta-8-THC | Yes (moderate) | CB1/CB2 partial agonist | Similar to THC but milder; less anxiety | Trace (mostly semi-synthetic) |
¶ The Entourage Effect
The entourage effect is a theory, first proposed by Raphael Mechoulam and Shimon Ben-Shabat in 1998, suggesting that the various compounds in cannabis -- cannabinoids, terpenes, flavonoids, and other molecules -- work synergistically to produce effects that differ from any single isolated compound.
Key evidence supporting the entourage effect:
- Sativex (THC:CBD 1:1 spray) is more effective for multiple sclerosis spasticity than THC alone
- Epidiolex (pure CBD) shows a bell-shaped dose-response, but full-spectrum extracts may have wider therapeutic windows
- Clinical observations consistently report that many patients prefer full-spectrum products over isolates, even at lower cannabinoid concentrations
However, the entourage effect remains an active area of research, and not all studies have confirmed synergistic interactions. The specific combinations and ratios of compounds that optimize therapeutic outcomes are still being determined.
For more on how terpenes contribute to the entourage effect, see Terpenes & the Entourage Effect.
¶ How Cannabinoid Profiles Vary by Strain
Every cannabis cultivar has a unique cannabinoid profile -- the specific percentages and ratios of cannabinoids it contains. These profiles are determined by:
- Genetics: The cultivar's inherited enzyme pathways determine which cannabinoids it primarily produces
- Growing conditions: Light, temperature, nutrients, and stress affect cannabinoid production
- Harvest timing: Earlier harvests tend to have more CBGA/THCA; later harvests show more conversion
- Curing and storage: Degradation over time converts THC to CBN and alters the overall profile
Modern cannabis cultivation has produced specialized cultivars targeting specific cannabinoid profiles:
| Profile Type | Description | Example Ratios |
|---|---|---|
| High-THC | Psychoactivity-focused; dominant in recreational market | THC >20%, CBD <1% |
| High-CBD | Non-intoxicating; medical-focused | CBD >10%, THC <1% |
| Balanced (1:1) | Moderate psychoactivity with CBD moderation | THC ~10%, CBD ~10% |
| High-CBG | Targeted non-intoxicating applications | CBG >10%, THC/CBD low |
| High-THCV | Specialized; energizing, appetite-suppressing | THCV >5% |
| Full-spectrum | Wide range of cannabinoids at natural ratios | Variable |
To explore specific strain profiles, see the Strains section.
¶ Lab Testing and Certificates of Analysis (COAs)
¶ What Is a COA?
A Certificate of Analysis (COA) is a document from an independent, accredited laboratory that reports the results of testing performed on a cannabis product. COAs are essential for verifying the contents and safety of cannabinoid products.
¶ What COAs Should Include
| Test Category | What It Measures | Why It Matters |
|---|---|---|
| Cannabinoid profile | Concentrations of THC, THCA, CBD, CBDA, CBG, CBN, CBC, and others | Potency verification; accurate dosing; chemotype classification |
| Terpene profile | Concentrations of individual terpenes | Indicates product quality; informs entourage effect |
| Residual solvents | Butane, propane, ethanol, etc. (for extracts) | Safety -- solvent residue can be harmful |
| Pesticides | Presence of prohibited agricultural chemicals | Safety -- especially critical for inhaled products |
| Heavy metals | Lead, cadmium, arsenic, mercury | Safety -- cannabis is a bioaccumulator |
| Microbial contaminants | Mold, bacteria (E. coli, Salmonella), yeast, aflatoxins | Safety -- particularly for immunocompromised users |
| Mycotoxins | Toxic compounds from mold | Safety -- concentrated in extracts |
| Moisture content | Water percentage in flower | Quality indicator; mold prevention |
| Water activity (Aw) | Available water for microbial growth | Safety threshold for storage |
¶ Reading a COA
When reviewing a COA:
- Verify the lab: Ensure the testing laboratory is accredited and independent (not affiliated with the producer)
- Check batch/lot numbers: Match the COA to your specific product batch
- Verify potency matches the label: Total THC = THCA × 0.877 + Delta-9-THC (the 0.877 factor accounts for CO2 loss during decarboxylation)
- Review contaminant results: All values should be below regulatory limits
- Look for "Pass" or "Compliant": The overall result should indicate the product meets safety standards
Note: In regulated cannabis markets, COAs are mandatory and publicly accessible. In unregulated or hemp-derived cannabinoid markets, COAs may be voluntary and of varying quality. Always request and review COAs before purchasing cannabinoid products.
¶ Consumption Methods and Cannabinoid Bioavailability
How cannabinoids are consumed significantly affects their absorption, onset, and duration:
| Method | Onset | Duration | Bioavailability | Notes |
|---|---|---|---|---|
| Inhalation (smoking) | 1-5 min | 1-3 hours | ~25-31% | Rapid onset; combustion byproducts |
| Inhalation (vaporizing) | 1-5 min | 1-3 hours | ~30-46% | Cleaner than smoking; temperature-dependent |
| Sublingual (tinctures) | 15-45 min | 4-6 hours | ~13-35% | Bypasses first-pass metabolism; variable absorption |
| Oral (edibles/capsules) | 30-120 min | 6-8+ hours | ~4-20% | First-pass metabolism converts THC to 11-OH-THC (more potent); highly variable |
| Topical | Variable | Variable | Minimal systemic | Localized; does not typically produce psychoactive effects |
| Transdermal patch | 30-60 min | 8-24 hours | Variable | Designed for systemic delivery through skin |
| Rectal | 15-45 min | 6-8 hours | ~50%+ (estimated) | Higher bioavailability; limited psychoactive effects |
For more on consumption methods, see Consumption Methods.
¶ Related Resources
- Terpenes & the Entourage Effect -- How aromatic compounds interact with cannabinoids
- Strains -- Cultivar-specific cannabinoid profiles
- Consumption Methods -- How different methods affect cannabinoid absorption
- Extraction -- Methods for isolating cannabinoids from plant material
- Cultivation Nutrients -- How nutrient management affects cannabinoid production
- Glossary -- Definitions of cannabis science terminology
- Modern Legalization -- The history of cannabis legalization and its impact on research
¶ References
- Mechoulam, R., & Gaoni, Y. (1965). Hashish -- XI. On the nature of the cannabinol transformation. Tetrahedron, 21(5), 1223-1229.
- Mechoulam, R., & Ben-Shabat, S. (1998). An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoidal activity. European Journal of Pharmacology, 359(1), R1-R2.
- Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta-9-tetrahydrocannabinol, cannabidiol and Delta-9-tetrahydrocannabivarin. British Journal of Pharmacology, 153(2), 199-215.
- Devinsky, O., et al. (2017). Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. New England Journal of Medicine, 376(21), 2011-2020.
- Iffland, K., & Grotenhermen, F. (2017). An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies. Cannabis and Cannabinoid Research, 2(1), 139-154.
- Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344-1364.
- National Academies of Sciences, Engineering, and Medicine. (2017). The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press.
- Borgelt, L. M., et al. (2013). The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy, 33(2), 195-209.
- Citti, C., et al. (2019). A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Delta-9-tetrahydrocannabinol: Delta-9-tetrahydrocannabiphorol. Scientific Reports, 9, 20335.
- World Health Organization. (2018). Cannabidiol (CBD) Critical Review Report. Expert Committee on Drug Dependence.
- Devane, W. A., Hanus, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., ... & Mechoulam, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258(5090), 1946-1949.
- Stella, N., Schweitzer, P., & Piomelli, D. (1997). A second endogenous cannabinoid that modulates long-term potentiation. Nature, 388(6644), 773-778.
- Hirvonen, J., et al. (2016). Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Molecular Psychiatry, 17(6), 642-649.
- Huestis, M. A. (2007). Human cannabinoid pharmacokinetics. Chemistry & Biodiversity, 4(8), 1770-1804.
- D'Addario, C., et al. (2021). Epigenetic mechanisms in the endocannabinoid system: New therapeutic opportunities? Pharmacological Research, 163, 105295.
- Allsop, D. J., et al. (2014). Cannabinoid withdrawal in cannabis users: A systematic review of the literature. Current Drug Abuse Reviews, 7(1), 46-62.
- Crippa, J. A., et al. (2019). Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. European Journal of Pain, 23(1), 136-147.
- Klein, C., et al. (2017). Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical Pharmacokinetics, 56(8), 825-842.
Last updated: April 2026